Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Strong topline growth driven by solid performance across key brands.
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Subscribe To Our Newsletter & Stay Updated